格隆汇8月11日丨药易购(300937.SZ)公布2025年半年度报告，上半年公司实现营业收入21.57亿元，同比 下降3.06%；归属于上市公司股东的净利润-761.44万元；归属于上市公司股东的扣除非经常性损益的净 利润-832.31万元；基本每股收益-0.08元。 ...

Core Viewpoint - The report highlights the financial performance and strategic initiatives of Sichuan Hezhong Yaoyigou Pharmaceutical Co., Ltd. for the first half of 2025, indicating a decline in revenue and net profit, while outlining the company's focus on expanding its healthcare ecosystem and digital transformation efforts [1][3][4]. Financial Performance - The company's revenue for the reporting period was approximately CNY 2.16 billion, a decrease of 3.06% compared to the same period last year [3]. - The net profit attributable to shareholders was a loss of CNY 7.61 million, representing a decline of 162.95% year-on-year [3]. - The basic earnings per share were reported at -0.08 CNY, down 161.54% from the previous year [3]. - Total assets increased by 1.91% to approximately CNY 1.75 billion compared to the end of the previous year [3]. Business Strategy - The company has been focusing on the outpatient pharmaceutical distribution market since its establishment in 2007, leveraging its technological capabilities and infrastructure to build a comprehensive health ecosystem [4][5]. - The strategy includes expanding upstream in the supply chain through product diversification, brand operation, and mergers and acquisitions to enhance pricing power [5][6]. - The company aims to develop a "golden product" ecosystem in specific disease areas by investing in ethnic medicine, traditional Chinese medicine, and medical devices [5][6][7]. Digital Transformation - The company is enhancing its digital capabilities by investing in AI-driven retail systems and establishing a comprehensive supply chain management platform [6][12]. - It has developed a digital medicine distribution business that includes B2B e-commerce and retail operations, covering over 20,000 pharmaceutical products [12][14]. - The company is also focusing on building a smart retail ecosystem that integrates online and offline channels to improve customer engagement and service delivery [15][20]. Brand Development - The company has established several key brands, including "Weige" and "Youshili," which have gained significant market traction in their respective categories [10][16]. - It is actively promoting traditional Chinese medicine brands and has secured exclusive distribution rights for several innovative products [7][8][10]. - The company is leveraging content marketing and digital platforms to enhance brand visibility and consumer engagement [10][17]. Investment and Partnerships - The company has formed strategic partnerships with various pharmaceutical manufacturers and research organizations to enhance its product offerings and market reach [7][8][19]. - It is also investing in health technology and wearable medical devices to support chronic disease management and health monitoring [9][11]. - The establishment of the "Jiansu Yigou Fund" aims to invest in high-quality pharmaceutical products and innovative sales channels, creating a synergistic effect with the company's existing operations [20].

Core Points - The company reported a decrease in revenue and a significant net loss for the first half of 2025 compared to the same period in the previous year [1][3] - The company plans not to distribute cash dividends or issue bonus shares [1] Financial Performance - Revenue for the reporting period was approximately CNY 2.16 billion, down 3.06% from CNY 2.23 billion in the previous year [1] - The net profit attributable to shareholders was a loss of approximately CNY 7.61 million, a decline of 162.95% from a profit of CNY 12.10 million in the same period last year [1] - The net profit after deducting non-recurring gains and losses was a loss of approximately CNY 8.32 million, down 198.14% from a profit of CNY 8.48 million [1] - The net cash flow from operating activities was a negative CNY 7.28 million, a decrease of 315.44% from a positive CNY 3.38 million [1] - Basic and diluted earnings per share were both negative CNY 0.08, compared to positive CNY 0.13 in the previous year [1] Assets and Equity - Total assets at the end of the reporting period were approximately CNY 1.75 billion, an increase of 1.91% from CNY 1.72 billion at the end of the previous year [3] - Net assets attributable to shareholders were approximately CNY 832.35 million, down 2.02% from CNY 849.54 million at the end of the previous year [3] Shareholder Information - The company had a total of 15,032 common shareholders at the end of the reporting period [3] - Li Yanfei is the controlling shareholder and actual controller of the company, holding 36.97% of the shares [4]

Group 1 - The board meeting of Sichuan Hezhong Yaoyigou Pharmaceutical Co., Ltd. was held on August 10, 2025, via communication voting, with all 9 directors present [1] - The board approved the preparation of the company's 2025 semi-annual report and its summary, ensuring the report accurately reflects the company's actual situation without any false records or misleading statements [1][2] - The voting results for the proposal were unanimous, with 9 votes in favor, 0 against, and 0 abstentions [2] Group 2 - The notice for the board meeting was communicated to all directors on July 31, 2025, through written and telephone methods [1] - The meeting was convened and presided over by Chairman Chen Shunjun, with senior management in attendance [1] - The proposal was reviewed and approved by the company's board audit committee prior to the board meeting [2]

股票代码：300937 股票简称：药易购 公告编号：2025-040 四川合纵药易购医药股份有限公司 关于公司 2025 年半年度计提减值准备及 终止确认部分递延所得税资产的公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记 载、误导性陈述或重大遗漏。 四川合纵药易购医药股份有限公司（以下简称"公司"或"本公司"）根据 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》 《企业会计准则》以及公司相关会计政策的规定，计提了信用减值损失及资产减 值损失、终止确认部分递延所得税资产，现将具体情况公告如下： 一、本次计提减值准备原因和情况概述 根据《企业会计准则》等相关规定的要求，为真实准确地反映公司截至2025 年6月30日的财务状况和经营成果，公司对截至2025年6月30日的应收账款、应收 票据、其他应收款、商誉、存货等各类资产进行了减值测试，对可能存在减值迹 象的资产计提减值准备。2025年上半年，公司计提减值损失共计19,070,523.37元， 其中信用减值损失12,660,591.75元，资产减值损失6,409,931.62元。 本次计提减值准备的范围和总金额如 ...

四川合纵药易购医药股份有限公司 单位：人民币万 | 元 | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 上市公司 2025 年 | | | | 半年度 | | 半年年 | | | | | 占用方与上市公司的 | | | | 占用累计 | | 占用 | | | | | 资 非经营性资金占用 | | 占用形成 资金占用方名称 | | 占用 | 核算的 | 期初占用 | | | | 偿还 | | | 累 期末占 | | | | | | | | | | | | | | | 关联关系 | | | | 发生金额 | | 金的利 | | | 原 | | 因 性质 | | | | | | | | | | | | | | | | | 会计科目 | 资金余额 | | | | 计发生 | 用资金 | | | | | | | | （不含利息） | | 息（如 | | | | | | | | | | | | | | 金额 | 余额额 | | | | | | | | | ...

（文章来源：每日经济新闻） 药易购（SZ 300937，收盘价：31.62元）8月11日晚间发布半年度业绩报告称，2025年上半年营业收入 约21.57亿元，同比减少3.06%；归属于上市公司股东的净利润亏损约761万元；基本每股收益亏损0.08 元。 ...

四川合纵药易购医药股份有限公司（以下简称"公司"）第四届董事会第二 次会议于 2025 年 8 月 10 日以通讯表决方式召开。本次董事会会议的通知于 2025 年 7 月 31 日以书面、电话方式通知全体董事。会议应出席董事 9 名，实际出席 董事 9 名。本次董事会会议由董事长陈顺军先生召集并主持，公司高级管理人员 列席了本次会议。本次会议的召集、召开和表决程序符合国家有关法律、行政法 规、部门规章、规范性文件及《四川合纵药易购医药股份有限公司章程》的规定。 二、董事会会议审议情况 经与会董事审议，以投票表决方式审议了以下议案： 1、审议通过《关于公司<2025 年半年度报告>（全文及摘要）的议案》 公司严格按照相关法律、行政法规、中国证券监督管理委员会、深圳证券交 易所的规定，编制公司《2025 年半年度报告》及《2025 年半年度报告摘要》， 报告内容真实、准确、完整地反映了公司的实际情况，不存在任何虚假记载、误 导性陈述或者重大遗漏。 证券代码：300937 证券简称：药易购 公告编号：2025-039 四川合纵药易购医药股份有限公司 第四届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披 ...

| | 重庆鑫斛药房连锁 | 公司持有其 5%股权并 | 应收账款 | 686.67 | 1,238.05 | -- | 731.20 | 1,193.52 | 出售商 品、提供 综合服务 | 经营性 往来 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 有限公司 | 委派一名董事 | 应收票据 | 2.86 | -- | -- | 2.86 | -- | 出售商品 | 经营性 | | | | | | | | | | | | 往来 | | | 杭州雕弧科技有限 公司 | 陈顺军控制的四川神 鸟世纪科技有限公司 | 其他应收款 | 0.21 | -- | -- | 0.21 | -- | 提供综合 管理服务 | 经营性 往来 | | | | 之控股子公司 | | | | | | | | | | | 总计 | | | 3,494.79 | 7,847.08 | -- | 6,574.03 | 4,767.84 | -- | -- | | 法定代表人：李燕飞 | | | | 主管会计工作负责人：郑德强 | | | | ...

公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记 四川合纵药易购医药股份有限公司（以下简称"公司"或"本公司"）根据 《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》 《企业会计准则》以及公司相关会计政策的规定，计提了信用减值损失及资产减 值损失、终止确认部分递延所得税资产，现将具体情况公告如下： 一、本次计提减值准备原因和情况概述 根据《企业会计准则》等相关规定的要求，为真实准确地反映公司截至2025 年6月30日的财务状况和经营成果，公司对截至2025年6月30日的应收账款、应收 票据、其他应收款、商誉、存货等各类资产进行了减值测试，对可能存在减值迹 象的资产计提减值准备。2025年上半年，公司计提减值损失共计19,070,523.37元， 其中信用减值损失12,660,591.75元，资产减值损失6,409,931.62元。 本次计提减值准备的范围和总金额如下： 股票代码：300937 股票简称：药易购 公告编号：2025-040 四川合纵药易购医药股份有限公司 关于公司 2025 年半年度计提减值准备及 终止确认部分递延所得税资产的公告 | 项目 | 2025 ...